Posters

Regulatory authorities are active to ensure a good regulatory environment for somatic cell therapy-, gene therapy- and tissue engineering products (in the EU known as ‘Advanced Therapy Medicinal Products’). Both the EMEA and the FDA have, amongst others, issued guidelines to address the specific aspects of these products

Human embryonic stem cells (hESC) are promising for tissue engineering (TE) purposes due to their unique properties. However, the current standard mechanical passaging technique is time consuming and labour intensive, thus limiting the rate of hESC expansion and possible TE experiments.

This study investigated whether adipose-derived stem cells (ADSC), cultivated in the medium containing autologous serum, maintain immunomodulatory properties of MSC. Obtained cells were CD73, CD90 and CD105 positive but CD34 and CD45 negative. ADSC underwent in vitro differentiation into adipocytes, osteoblasts and chondroblasts. Immunomodulatory properties of ADSC were investigated by blast transformation reaction and significant suppression of T lymphocyte proliferation was induced in a dose d

Efforts to elucidate the mechanisms by which HBV infects hepatocytes and causes liver damage have been hampered by the strict virus host range and a lack of suitable cell culture and animal models of HBV infection/replication. The present study has established and elucidated a novel HBV infection/replication in vitro model system based on adipose-derived stem cells differentiated into human hepatocyte-like cell line.

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disorder of the CNS. No successful treatment for MS, but one therapeutic strategy in research is the use of bone marrow-derived mesenchymal stem cells (MSC). We studied a group of MS patients who underwented MSCs, assayed for expression of a transcription factor, FOXP3, as a specific marker of MS amelioration in peripheral blood. qRT-PCR on PBMCs showed higher FoxP3 levels.

A growing demand for study of cells within biologically realistic, in vitro, microenvironments requires a paradigm shift in cell culture technology: from cell culture on 2-D, rigid substrata to cell growth within a 3-D space, defined by malleable materials composed of biologically “smart” compounds.1, 2 Therapeutic issues addressed by tissue engineering and regenerative medicine require similar materials, customized for human application in a wide variety of treatment circumstances: ranging

Here we have used previously described methods to bioengineer teeth from human dental stem cells (hDSC). We we were able to demonstrate that dissociated hDSC-seeded polymer constructs can form bioengineered teeth that are morphologically similar to natural human teeth at both gross and microscopic levels. We anticipate that further modifications of this approach will eventually result in reliable methods to bioengineer replacement teeth in humans.

Defined and feeder-independent cell culture systems provide a platform for greater reproducibility and standardization in human pluripotent stem cell (hPSC) research, mTeSR 1 has become the most widely cited feeder independent system for the culture of undifferentiated human ES and iPSC.

Human ADSCs (Adipose derived stem cells) could represent an interesting therapy to apply in heart infarction and, more in general, in regenerative medicine. Furthermore, these cells have at least three advantages: good amounts of starting material, expansion feasibility and no ethical restrictions.